Renaissance Capital logo

PepGen Priced, Nasdaq: PEPG

Phase 1 biotech developing oligonucleotide therapies for neuromuscular diseases.

Industry: Health Care

Latest Trade: $4.32 0.00 (0.0%)

First Day Return: +7.4%

Return from IPO: -64.0%

Industry: Health Care

We are a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Our Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. This technology was initially developed through a collaboration between researchers at the University of Oxford and the Medical Research Council of United Kingdom Research and Innovation. We have in-licensed an extensive patent portfolio from these institutions to support the further advancement and potential commercialization of our EDO platform. Our EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery, and in preclinical studies we have observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system, or CNS.
more less
IPO Data
IPO File Date 04/15/2022
Offer Price $12.00
Price Range $13.00 - $15.00
Offer Shares (mm) 9.0
Deal Size ($mm) $108
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 05/05/2022
Offer Price $12.00
Price Range $13.00 - $15.00
Offer Shares (mm) 9.0
Deal Size ($mm) $108
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
BofA Securities
Leerink Partners
more
Company Data
Headquarters Cambridge, MA, United States
Founded 2018
Employees at IPO 31
Website pepgen.com

PepGen (PEPG) Performance